ohnson & Johnson Pharmaceutical Research & Development. L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
(J&JPRD) is part of Johnson & Johnson, the world's most broad-based
producer of healthcare products. J&JPRD is headquartered in Raritan, New
Jersey (USA), and has facilities throughout Europe and the United States.
J&JPRD is leveraging drug discovery and drug development in a variety of
therapeutic areas to address unmet medical needs worldwide.
About Ortho Biotech Products, L.P.
Ortho Biotech Products, L.P. is a leading biopharmaceutical company
devoted to helping improve the lives of patients with cancer and with
anemia due to multiple causes, including chronic kidney disease. Since it
was founded in 1990, Ortho Biotech and its worldwide affiliates have earned
a global reputation for researching, manufacturing and marketing innovative
products that enhance patients' health. Located in Bridgewater, N.J., Ortho
Biotech is an established market leader in Epoetin alfa therapy for anemia
management. The company also markets treatments for recurrent ovarian
cancer, rejection of transplanted organs and other serious illnesses. For
more information, visit http://www.orthobiotech.com.
'/>"/>SOURCE Ortho Biotech Products, L.P. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results2.
Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control3.
Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results4.
Sygnis Pharma AG announces date for presentation of clinical
results5.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis6.
Positive Aggrastat Results Featured in the Journal of the American
College of Cardiology7.
Pixantrone Combination Therapy for First-line Treatment of
Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe
Toxicities Including Heart Damage When Compared to
Doxorubicin-based Therapy8.
Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society9.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone10.
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis11.
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis